Realizing the promise of personalized medicines for cancer
Clovis Oncology (NASDAQ: CLVS) is developing targeted cancer therapies in combination with companion diagnostics to ensure that the right drug gets to the right patients. The company's pipeline includes rociletinib, a mutant EGFR inhibitor for the treatment of non-small cell lung cancer and rucaparib, a PARP inhibitor for treatment of ovarian cancer. Both drugs have received Breakthrough Therapy designation from the FDA. Clovis completed its IPO in 2011.